IMC Chicago’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$631K Sell
152,800
-14,000
-8% -$47.5K ﹤0.01% 4416
2026
Q2
$612K Buy
166,800
+84,000
+101% +$280K ﹤0.01% 4416
2026
Q1
$254K Sell
82,800
-54,400
-40% -$210K ﹤0.01% 4769
2025
Q4
$561K Sell
137,200
-40,600
-23% -$201K ﹤0.01% 3399
2025
Q3
$868K Buy
177,800
+43,500
+32% +$228K ﹤0.01% 2814
2025
Q2
$680K Sell
134,300
-52,200
-28% -$256K ﹤0.01% 2703
2025
Q1
$987K Buy
+186,500
New +$1.36M ﹤0.01% 2283

Other funds holding RXRX

IMC Chicago's RXRX Position: Q3 2026 in Review

IMC Chicago opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 114,576 shares worth $473K. The stake represents ﹤0.01% of the portfolio and ranks #4754 among its holdings. This is a return to the name: IMC Chicago previously reported a position in RXRX as recently as Q3 2025.

IMC Chicago first reported a position in RXRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $968K in Q1 2025. 354 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • IMC Chicago held 114,576 shares of Recursion Pharmaceuticals worth $473K as of Q3 2026.
  • Recursion Pharmaceuticals was a new IMC Chicago position in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #4754 holding.
  • IMC Chicago first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • IMC Chicago's Recursion Pharmaceuticals position peaked at $968K in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.